MA39996A - Oligomères et conjugués d'oligomères - Google Patents

Oligomères et conjugués d'oligomères

Info

Publication number
MA39996A
MA39996A MA039996A MA39996A MA39996A MA 39996 A MA39996 A MA 39996A MA 039996 A MA039996 A MA 039996A MA 39996 A MA39996 A MA 39996A MA 39996 A MA39996 A MA 39996A
Authority
MA
Morocco
Prior art keywords
oligomer
oligomers
oligomer conjugates
viral disorder
hbx
Prior art date
Application number
MA039996A
Other languages
English (en)
Inventor
Hassan Javanbakht
Morten Lindow
Søren Ottosen
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA39996A publication Critical patent/MA39996A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1133—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against herpetoviridae, e.g. HSV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Botany (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)

Abstract

La présente invention concerne un conjugué d'oligomère destiné à être utilisé pour traiter une pathologie virale. Ledit conjugué d'oligomère comprend : a) un oligomère capable de moduler une séquence cible de la protéine x et/ou de hbsag du virus de l'hépatite b (vhb) pour traiter une pathologie virale; et b) un véhicule capable d'acheminer l'oligomère jusqu'au foie, ledit véhicule étant lié, de préférence conjugué, à l'oligomère.
MA039996A 2014-05-15 2015-05-12 Oligomères et conjugués d'oligomères MA39996A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1408623.5A GB201408623D0 (en) 2014-05-15 2014-05-15 Oligomers and oligomer conjugates

Publications (1)

Publication Number Publication Date
MA39996A true MA39996A (fr) 2015-11-19

Family

ID=51134907

Family Applications (2)

Application Number Title Priority Date Filing Date
MA039996A MA39996A (fr) 2014-05-15 2015-05-12 Oligomères et conjugués d'oligomères
MA49715A MA49715B1 (fr) 2014-05-15 2015-05-12 Oligomères et conjugués d'oligomères

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA49715A MA49715B1 (fr) 2014-05-15 2015-05-12 Oligomères et conjugués d'oligomères

Country Status (33)

Country Link
US (4) US10421967B2 (fr)
EP (2) EP3143142A2 (fr)
JP (4) JP6306745B2 (fr)
KR (3) KR101878587B1 (fr)
CN (3) CN118286449A (fr)
AR (1) AR100445A1 (fr)
AU (2) AU2015260991B2 (fr)
BR (1) BR112016026777A2 (fr)
CA (1) CA2948946A1 (fr)
CL (2) CL2016002849A1 (fr)
CR (1) CR20160520A (fr)
DK (1) DK3550023T3 (fr)
EA (1) EA034924B1 (fr)
ES (1) ES3050007T3 (fr)
FI (1) FI3550023T3 (fr)
GB (1) GB201408623D0 (fr)
HR (1) HRP20250974T1 (fr)
HU (1) HUE072453T2 (fr)
IL (1) IL248526A0 (fr)
LT (1) LT3550023T (fr)
MA (2) MA39996A (fr)
MX (1) MX2016014866A (fr)
MY (1) MY176428A (fr)
PE (1) PE20170262A1 (fr)
PH (1) PH12016502102A1 (fr)
PL (1) PL3550023T3 (fr)
PT (1) PT3550023T (fr)
RS (1) RS67099B1 (fr)
SG (2) SG11201609501WA (fr)
SI (1) SI3550023T1 (fr)
TW (2) TW201825101A (fr)
WO (1) WO2015173208A2 (fr)
ZA (1) ZA201607251B (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120095397A (ko) 2009-10-16 2012-08-28 글락소 그룹 리미티드 Ｈｂｖ 안티센스 억제제
GB201408623D0 (en) 2014-05-15 2014-07-02 Santaris Pharma As Oligomers and oligomer conjugates
US20170137821A1 (en) 2015-07-17 2017-05-18 Arcturus Therapeutics, Inc. Molecules and agents for treating hepatitis b virus
WO2017015175A1 (fr) 2015-07-17 2017-01-26 Arcturus Therapeutics, Inc. Compositions et agents contre le virus de l'hépatite b et utilisations de ceux-ci
EP3472346B1 (fr) 2016-06-17 2023-01-18 F. Hoffmann-La Roche AG Inhibiteurs de papd5 et papd7 pour le traitement d'une infection par l'hépatite b
US11542294B2 (en) 2017-03-29 2023-01-03 Roche Innovation Center Copenhagen A/S Rapid unylinker cleavage
WO2018215049A1 (fr) * 2017-05-23 2018-11-29 F. Hoffmann-La Roche Ag Procédé de préparation de conjugués d'oligonucléotides galnac
CN111527207B (zh) 2017-09-14 2024-04-26 詹森生物制药有限公司 GalNAc衍生物
TW202424191A (zh) * 2017-10-16 2024-06-16 瑞士商赫孚孟拉羅股份公司 用於降低PAPD5及PAPD7 mRNA以治療B型肝炎感染之核酸分子
MY201698A (en) * 2017-10-20 2024-03-13 Dicerna Pharmaceuticals Inc Methods for treating hepatitis b infection
SG11202009680XA (en) 2018-04-05 2020-10-29 Hoffmann La Roche Use of fubp1 inhibitors for treating hepatitis b virus infection
PE20220013A1 (es) 2018-07-03 2022-01-11 Hoffmann La Roche Oligonucleotidos para modular la expresion de tau
BR112021000538A2 (pt) 2018-07-13 2021-04-06 F. Hoffmann-La Roche Ag Oligonucleotídeos para modular a expressão de rtel1
US11466274B2 (en) * 2019-05-31 2022-10-11 Aligos Therapeutics, Inc. Modified gapmer oligonucleotides and methods of use
EP4031140A1 (fr) 2019-09-20 2022-07-27 F. Hoffmann-La Roche AG Procédé de traitement d'une infection par le virus de l'hépatite b à l'aide d'un modulateur allostérique de protéine centrale
JP7653997B2 (ja) 2019-12-19 2025-03-31 エフ． ホフマン－ラ ロシュ アーゲー Ｂ型肝炎ウイルス感染を処置するためのｃｏｐｓ３阻害剤の使用
CN114867856A (zh) 2019-12-19 2022-08-05 豪夫迈·罗氏有限公司 Saraf抑制剂用于治疗乙型肝炎病毒感染的用途
JP7634542B2 (ja) 2019-12-19 2025-02-21 エフ． ホフマン－ラ ロシュ アーゲー Ｂ型肝炎ウイルス感染症を処置するためのｓｅｐｔ９阻害剤の使用
JP2023506540A (ja) 2019-12-19 2023-02-16 エフ． ホフマン－ラ ロシュ エージー． Ｂ型肝炎ウイルス感染を処置するためのｓｃａｍｐ３阻害剤の使用
CN114829601A (zh) 2019-12-19 2022-07-29 豪夫迈·罗氏有限公司 Sbds抑制剂用于治疗乙型肝炎病毒感染的用途
EP4081217A1 (fr) 2019-12-24 2022-11-02 F. Hoffmann-La Roche AG Association pharmaceutique d'agents antiviraux ciblant le vhb et/ou un modulateur immunitaire pour le traitement du vhb
EP4081639A1 (fr) * 2019-12-24 2022-11-02 F. Hoffmann-La Roche AG Association pharmaceutique d'un oligonucléotide thérapeutique ciblant le vhb et un agoniste de tlr7 pour le traitement du vhb
AU2020415307A1 (en) 2019-12-24 2022-06-09 F. Hoffmann-La Roche Ag Method of treating virus infection using a TLR7 agonist
WO2021207641A1 (fr) * 2020-04-10 2021-10-14 Aligos Therapeutics, Inc. Molécules d'oligonucléotide antisens (aso) et leurs utilisations pour des maladies à coronavirus
WO2021249484A1 (fr) * 2020-06-10 2021-12-16 南京明德新药研发有限公司 Groupe conjugué et conjugué
AR122731A1 (es) 2020-06-26 2022-10-05 Hoffmann La Roche Oligonucleótidos mejorados para modular la expresión de fubp1
JP2023538630A (ja) 2020-08-21 2023-09-08 エフ． ホフマン－ラ ロシュ アーゲー Ｂ型肝炎ウイルス感染症を処置するためのａ１ｃｆ阻害剤の使用
CN116546989A (zh) * 2020-10-09 2023-08-04 阿达尔克斯制药有限公司 N-乙酰半乳糖胺（GalNAc）来源的化合物和寡核苷酸
MX2023004170A (es) * 2020-10-09 2023-06-27 Adarx Pharmaceuticals Inc Compuestos y oligonucleótidos derivados de n-acetilgalactosamina (galnac).
TW202246500A (zh) 2021-02-02 2022-12-01 瑞士商赫孚孟拉羅股份公司 用於抑制 ｒｔｅｌ１ 表現之增強型寡核苷酸
IL312635A (en) 2021-11-11 2024-07-01 Hoffmann La Roche Pharmaceutical combinations for treatment of hbv
WO2023111210A1 (fr) 2021-12-17 2023-06-22 F. Hoffmann-La Roche Ag Combinaison d'oligonucléotides pour moduler rtel1 et fubp1
TW202340468A (zh) 2022-01-10 2023-10-16 中國大陸商杭州浩博醫藥有限公司 B型肝炎病毒(hbv)表現之調節
AU2023236560A1 (en) * 2022-03-17 2024-10-03 Aligos Therapeutics, Inc. Modified gapmer oligomers and methods of use thereof
WO2025264546A1 (fr) * 2024-06-18 2025-12-26 Sirius Therapeutics, Inc. Compositions de conjugués lipide-acide polynucléique et leurs utilisations

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5927900A (ja) 1982-08-09 1984-02-14 Wakunaga Seiyaku Kk 固定化オリゴヌクレオチド
US4948882A (en) 1983-02-22 1990-08-14 Syngene, Inc. Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis
US4587044A (en) 1983-09-01 1986-05-06 The Johns Hopkins University Linkage of proteins to nucleic acids
JPH0660613B2 (ja) 1983-10-11 1994-08-10 ヤマハ発動機株式会社 車両のキツク式起動装置
US4740463A (en) 1984-04-13 1988-04-26 Massachusetts Institute Of Technology Methods and artificial genes for antagonizing the function of an oncogene
US5430136A (en) 1984-10-16 1995-07-04 Chiron Corporation Oligonucleotides having selectably cleavable and/or abasic sites
US4962029A (en) 1987-10-02 1990-10-09 Cetus Corporation Covalent oligonucleotide-horseradish peroxidase conjugate
US4914210A (en) 1987-10-02 1990-04-03 Cetus Corporation Oligonucleotide functionalizing reagents
US5525465A (en) 1987-10-28 1996-06-11 Howard Florey Institute Of Experimental Physiology And Medicine Oligonucleotide-polyamide conjugates and methods of production and applications of the same
DE3738460A1 (de) 1987-11-12 1989-05-24 Max Planck Gesellschaft Modifizierte oligonukleotide
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5391723A (en) 1989-05-31 1995-02-21 Neorx Corporation Oligonucleotide conjugates
EP0403716B1 (fr) 1989-06-22 1995-09-13 International Business Machines Corporation Dispositif d'annulation d'écho à ajustement des coefficients de l'annuleur d'écho pendant la transmission en duplex intégral
US5254469A (en) 1989-09-12 1993-10-19 Eastman Kodak Company Oligonucleotide-enzyme conjugate that can be used as a probe in hybridization assays and polymerase chain reaction procedures
GB8921710D0 (en) 1989-09-26 1989-11-08 Mentholatum Co Ltd Ibuprofen triturates and topical compositions containing same
WO1991004753A1 (fr) 1989-10-02 1991-04-18 Cetus Corporation Conjugues d'oligonucleotides non codants et leurs emplois therapeutiques
US5486603A (en) 1990-01-08 1996-01-23 Gilead Sciences, Inc. Oligonucleotide having enhanced binding affinity
US5138045A (en) 1990-07-27 1992-08-11 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
US5608046A (en) 1990-07-27 1997-03-04 Isis Pharmaceuticals, Inc. Conjugated 4'-desmethyl nucleoside analog compounds
US5245022A (en) 1990-08-03 1993-09-14 Sterling Drug, Inc. Exonuclease resistant terminally substituted oligonucleotides
US5512667A (en) 1990-08-28 1996-04-30 Reed; Michael W. Trifunctional intermediates for preparing 3'-tailed oligonucleotides
CA2095212A1 (fr) 1990-11-08 1992-05-09 Hybridon, Inc. Incorporation de multiples groupes de ligands sur des oligonucleotides synthetiques
WO1993001286A2 (fr) 1991-06-28 1993-01-21 Massachusetts Institute Of Technology Therapie localisee utilisant des oligonucleotides
DE59209203D1 (de) 1991-08-28 1998-03-26 Boehringer Mannheim Gmbh Primer für matrizenabhängige enzymatische nukleinsäuresynthesen
AU2314592A (en) 1992-03-25 1993-10-21 Dactylamatic, Inc. Fingerprint observation and recording system
US20040127446A1 (en) 1992-05-14 2004-07-01 Lawrence Blatt Oligonucleotide mediated inhibition of hepatitis B virus and hepatitis C virus replication
WO2002081494A1 (fr) * 2001-03-26 2002-10-17 Sirna Therapeutics, Inc. Inhibition regulee par des oligonucleotides de la replication du virus de l'hepatite b et du virus de l'hepatite c
US20040054156A1 (en) * 1992-05-14 2004-03-18 Kenneth Draper Method and reagent for inhibiting hepatitis B viral replication
US20030206887A1 (en) * 1992-05-14 2003-11-06 David Morrissey RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA)
NL9201440A (nl) 1992-08-11 1994-03-01 Univ Leiden Triantennaire clusterglycosiden, hun bereiding en toepassing.
US5574142A (en) 1992-12-15 1996-11-12 Microprobe Corporation Peptide linkers for improved oligonucleotide delivery
US5652332A (en) 1993-03-12 1997-07-29 Xoma Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
US6413949B1 (en) 1995-06-07 2002-07-02 D-Pharm, Ltd. Prodrugs with enhanced penetration into cells
WO1995017414A1 (fr) 1993-12-23 1995-06-29 Apollon, Inc. Oligonucleotides anti-hbv
US5728518A (en) 1994-01-12 1998-03-17 The Immune Response Corporation Antiviral poly-and oligonucleotides
US5580731A (en) 1994-08-25 1996-12-03 Chiron Corporation N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith
DE69527857T2 (de) 1994-10-06 2003-05-28 Buchardt, Dorte Peptid-nukleinsäure-konjugate
US5856459A (en) 1995-06-06 1999-01-05 Hybridon, Inc. Oligonucleotides specific for hepatitis B virus
US5684142A (en) 1995-06-07 1997-11-04 Oncor, Inc. Modified nucleotides for nucleic acid labeling
JP4338106B2 (ja) 1995-06-07 2009-10-07 ライフ テクノロジーズ コーポレーション ペプチド増強カチオン脂質トランスフェクション
US5985662A (en) 1995-07-13 1999-11-16 Isis Pharmaceuticals Inc. Antisense inhibition of hepatitis B virus replication
JP2000501414A (ja) 1995-11-22 2000-02-08 ザ・ジョンズ・ホプキンス・ユニバーシティー 生体分子の細胞取り込みを高めるリガンド
AU3811897A (en) 1996-07-24 1998-02-10 Oglios Therapeutics, Inc. Antisense oligonucleotides as antibacterial agents
AU6769998A (en) 1997-03-26 1998-10-20 Board Of Regents, The University Of Texas System Methods and compositions for using membrane-penetrating proteins to carry materials across cell membranes
US5770716A (en) 1997-04-10 1998-06-23 The Perkin-Elmer Corporation Substituted propargylethoxyamido nucleosides, oligonucleotides and methods for using same
IL132941A0 (en) 1997-05-21 2001-03-19 Univ Leland Stanford Junior Composition and method for enhancing transport across biological membranes
US6610539B1 (en) 1997-07-10 2003-08-26 Genesense Technologies, Inc. Antisense oligonucleotide sequences as inhibitors of microorganisms
DE69829760T3 (de) 1997-09-12 2016-04-14 Exiqon A/S Bi- und tri-zyklische - nukleosid, nukleotid und oligonukleotid-analoga
US6096875A (en) 1998-05-29 2000-08-01 The Perlein-Elmer Corporation Nucleotide compounds including a rigid linker
EP1086126A1 (fr) 1998-06-10 2001-03-28 The Queen's University of Belfast Peptide permeable aux cellules
US6300319B1 (en) * 1998-06-16 2001-10-09 Isis Pharmaceuticals, Inc. Targeted oligonucleotide conjugates
US6335432B1 (en) 1998-08-07 2002-01-01 Bio-Red Laboratories, Inc. Structural analogs of amine bases and nucleosides
US6335437B1 (en) 1998-09-07 2002-01-01 Isis Pharmaceuticals, Inc. Methods for the preparation of conjugated oligomers
WO2000015265A1 (fr) 1998-09-16 2000-03-23 Vitagenix, Inc. Compositions et techniques permettant d'utiliser des mecanismes d'incorporation pour des applications diagnostiques et therapeutiques d'oligonucleotides ciblant des bacteries
CA2403243A1 (fr) * 1999-08-31 2001-03-08 Ribozyme Pharmaceuticals, Inc. Modulateurs d'expression genetique a base d'acide nucleique
US6617442B1 (en) 1999-09-30 2003-09-09 Isis Pharmaceuticals, Inc. Human Rnase H1 and oligonucleotide compositions thereof
CN100534436C (zh) 2001-11-21 2009-09-02 利兰·斯坦福青年大学托管委员会 多核苷酸
US7087229B2 (en) 2003-05-30 2006-08-08 Enzon Pharmaceuticals, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
EP2752488B1 (fr) 2002-11-18 2020-02-12 Roche Innovation Center Copenhagen A/S Conception antisens
DK1495769T3 (da) 2003-07-11 2008-06-23 Lbr Medbiotech B V Mannose-6-phosphat-receptormedieret gentransfer til muskelceller
WO2005021800A2 (fr) * 2003-08-22 2005-03-10 Sirna Therapeutics, Inc. Detection et quantification de molecules d'acide nucleique dans des echantillons biologiques
KR101117148B1 (ko) 2004-04-02 2012-03-07 후지필름 가부시키가이샤 착색제함유 경화성 조성물, 컬러필터 및 그 제조방법
WO2007031091A2 (fr) 2005-09-15 2007-03-22 Santaris Pharma A/S Composes antagonistes d'arn de modulation de l'expression de p21 ras
CA2640171C (fr) 2006-01-27 2014-10-28 Isis Pharmaceuticals, Inc. Analogues d'acides nucleiques bicycliques modifies en position 6
CA3044969A1 (fr) 2006-05-05 2007-12-21 Ionis Pharmaceuticals, Inc. Composes et procedes de modulation de l'expression genique
JP5441688B2 (ja) 2006-05-11 2014-03-12 アイシス ファーマシューティカルズ， インコーポレーテッド ５’修飾二環式核酸類似体
AU2007296055A1 (en) 2006-09-15 2008-03-20 Enzon Pharmaceuticals, Inc. Polymeric conjugates containing positively-charged moieties
CN101534643A (zh) 2006-09-15 2009-09-16 安佐制药股份有限公司 用于递送寡核苷酸的基于位阻酯的生物可降解连接体
US8580756B2 (en) 2007-03-22 2013-11-12 Santaris Pharma A/S Short oligomer antagonist compounds for the modulation of target mRNA
EP2170917B1 (fr) 2007-05-30 2012-06-27 Isis Pharmaceuticals, Inc. Analogues d'acides nucléiques bicycliques pontés par aminométhylène n-substitué
ES2386492T3 (es) 2007-06-08 2012-08-21 Isis Pharmaceuticals, Inc. Análogos de ácidos nucleicos bicíclicos carbocíclicos
CN101796062B (zh) 2007-07-05 2014-07-30 Isis制药公司 6-双取代双环核酸类似物
CN101342530A (zh) 2007-07-10 2009-01-14 陈镜图 一种小五金件生产检测分选系统及方法
WO2009060316A2 (fr) * 2007-09-14 2009-05-14 The Governors Of The University Of Alberta Polypeptides se liant au virus de l'hépatite b et leurs procédés d'utilisation
WO2009067647A1 (fr) 2007-11-21 2009-05-28 Isis Pharmaceuticals, Inc. Analogues d'acide nucléique alpha-l-bicyclique carbocyclique
WO2009090182A1 (fr) 2008-01-14 2009-07-23 Santaris Pharma A/S Oligonucléotides de type « gapmère » de nucléotide d'adn substitué en c4'
EP2265627A2 (fr) 2008-02-07 2010-12-29 Isis Pharmaceuticals, Inc. Analogues d acides nucléiques de cyclohexitol bicycliques
WO2009124238A1 (fr) 2008-04-04 2009-10-08 Isis Pharmaceuticals, Inc. Composés oligomères comprenant des nucléosides bicycliques terminaux liés de façon neutre
EP2274423A2 (fr) 2008-04-04 2011-01-19 Isis Pharmaceuticals, Inc. Composés oligomères comprenant des nucléosides bicycliques et ayant une toxicité réduite
WO2009126933A2 (fr) 2008-04-11 2009-10-15 Alnylam Pharmaceuticals, Inc. Délivrance spécifique à un site d'acides nucléiques en combinant des ligands de ciblage avec des composants endosomolytiques
DK2356129T3 (da) 2008-09-24 2013-05-13 Isis Pharmaceuticals Inc Substituerede alpha-L-bicykliske nukleosider
AR076053A1 (es) * 2009-04-14 2011-05-18 Schering Corp Derivados de pirazolo[1,5-a]pirimidina como inhibidores de mtor
WO2011017521A2 (fr) 2009-08-06 2011-02-10 Isis Pharmaceuticals, Inc. Analogues d'acides nucléiques cyclohexoses bicycliques
KR20120095397A (ko) * 2009-10-16 2012-08-28 글락소 그룹 리미티드 Ｈｂｖ 안티센스 억제제
WO2011085102A1 (fr) 2010-01-11 2011-07-14 Isis Pharmaceuticals, Inc. Nucléosides bicycliques à base modifiée et composés oligomères préparés à partir de ceux-ci
WO2011115818A1 (fr) 2010-03-17 2011-09-22 Isis Pharmaceuticals, Inc. Nucléosides bicycliques 5'-substitués et composés oligomères synthétisés à partir desdits nucléosides
JP2013537423A (ja) 2010-08-17 2013-10-03 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いたＢ型肝炎ウイルス（ＨＢＶ）遺伝子発現のＲＮＡ干渉媒介性阻害
CN105721131B (zh) 2010-12-13 2019-05-10 瑞典爱立信有限公司 交换与测量周期有关的参数
CA2816155C (fr) * 2010-12-17 2020-10-27 Arrowhead Research Corporation Fraction de ciblage complexe de galactose-modulateur pharmacocinetique pour arnsi
CA2822161C (fr) 2010-12-29 2018-05-29 Philipp Hadwiger Conjugues de petites molecules pour l'administration intracellulaire d'acides nucleiques
IT1404160B1 (it) 2010-12-30 2013-11-15 Incard Sa Metodo e sistema per calcolare una frequenza di clock di un segnale di clock per una carta a circuito integrato
TW201303013A (zh) * 2011-04-21 2013-01-16 Isis Pharmaceuticals Inc Ｂ型肝炎病毒（ｈｂｖ）表現之調節
MX347253B (es) * 2011-04-21 2017-04-20 Ionis Pharmaceuticals Inc Modulación de la expresión del virus de hepatitis b (vhb).
SG194751A1 (en) * 2011-06-30 2013-12-30 Arrowhead Res Corp Compositions and methods for inhibiting gene expression of hepatitis b virus
US9580708B2 (en) * 2011-09-14 2017-02-28 Rana Therapeutics, Inc. Multimeric oligonucleotides compounds
KR20140036498A (ko) * 2012-09-17 2014-03-26 김문섭 와이-클립 이어폰 줄정리기
JP6452614B2 (ja) 2012-11-15 2019-01-16 ロシュ イノベーション センター コペンハーゲン エーエス オリゴヌクレオチドコンジュゲート
DK2951305T3 (en) * 2013-01-30 2018-10-29 Hoffmann La Roche LNA oligonucleotide KULHYDRATKONJUGATER
PE20152002A1 (es) 2013-05-01 2016-01-21 Isis Pharmaceuticals Inc Composiciones y metodos para modular la expresion de ttr y vhb
SG10201908122XA (en) 2013-06-27 2019-10-30 Roche Innovation Ct Copenhagen As Antisense oligomers and conjugates targeting pcsk9
GB201408623D0 (en) 2014-05-15 2014-07-02 Santaris Pharma As Oligomers and oligomer conjugates
CN106795200B (zh) 2014-10-10 2020-06-19 豪夫迈·罗氏有限公司 Galnac亚磷酰胺、其核酸缀合物及其用途
EP3673080B1 (fr) 2017-08-25 2023-10-18 Stoke Therapeutics, Inc. Oligomères antisens pour le traitement d'états pathologiques et autres maladies

Also Published As

Publication number Publication date
PT3550023T (pt) 2025-08-14
MX2016014866A (es) 2017-02-27
EP3143142A2 (fr) 2017-03-22
TWI639432B (zh) 2018-11-01
JP2017515862A (ja) 2017-06-15
SG10201800655YA (en) 2018-02-27
JP6306745B2 (ja) 2018-04-04
CA2948946A1 (fr) 2015-11-19
US10767181B2 (en) 2020-09-08
SI3550023T1 (sl) 2025-10-30
RS67099B1 (sr) 2025-09-30
EA034924B1 (ru) 2020-04-07
KR101953074B1 (ko) 2019-02-27
US20210054381A1 (en) 2021-02-25
LT3550023T (lt) 2025-09-10
ZA201607251B (en) 2019-04-24
KR20170007414A (ko) 2017-01-18
CN106470688A (zh) 2017-03-01
US12281307B2 (en) 2025-04-22
US10421967B2 (en) 2019-09-24
AU2015260991B2 (en) 2019-01-17
BR112016026777A2 (pt) 2017-12-12
CN106470688B (zh) 2020-10-27
WO2015173208A2 (fr) 2015-11-19
HRP20250974T1 (hr) 2025-10-10
SG11201609501WA (en) 2016-12-29
KR20180008923A (ko) 2018-01-24
US20200024605A1 (en) 2020-01-23
GB201408623D0 (en) 2014-07-02
HUE072453T2 (hu) 2025-11-28
MY176428A (en) 2020-08-07
EP3550023B1 (fr) 2025-06-25
US20160010093A1 (en) 2016-01-14
KR20180081180A (ko) 2018-07-13
MA49715A (fr) 2019-10-09
CL2019000621A1 (es) 2019-07-26
FI3550023T3 (fi) 2025-08-25
AR100445A1 (es) 2016-10-05
US11591598B2 (en) 2023-02-28
CN112274647A (zh) 2021-01-29
CN112274647B (zh) 2024-04-23
EP3550023A1 (fr) 2019-10-09
DK3550023T3 (da) 2025-08-25
AU2019202556A1 (en) 2019-05-02
PH12016502102A1 (en) 2017-01-09
US20240035032A1 (en) 2024-02-01
AU2015260991A1 (en) 2016-11-17
TW201825101A (zh) 2018-07-16
ES3050007T3 (en) 2025-12-19
KR101878587B1 (ko) 2018-07-16
PL3550023T3 (pl) 2025-09-22
MA49715B1 (fr) 2025-09-30
WO2015173208A3 (fr) 2016-02-18
JP2022048397A (ja) 2022-03-25
JP6522814B2 (ja) 2019-05-29
WO2015173208A9 (fr) 2015-12-30
CL2016002849A1 (es) 2017-12-11
IL248526A0 (en) 2016-12-29
JP2018087202A (ja) 2018-06-07
JP2019108405A (ja) 2019-07-04
EA201692274A1 (ru) 2017-06-30
CR20160520A (es) 2017-01-06
CN118286449A (zh) 2024-07-05
TW201607541A (zh) 2016-03-01
PE20170262A1 (es) 2017-03-30

Similar Documents

Publication Publication Date Title
PH12016502102A1 (en) Oligomers and oligomer conjugates
PH12017500614A1 (en) Compositions and methods for silencing hepatitis b virus gene expression
PH12020550145A1 (en) Chemical Compounds
JOP20170161B1 (ar) عوامل RNAi للعدوى بفيروس التهاب الكبد ب
PH12018500573A1 (en) Hepatitis b core protein modulators
PH12017550022A1 (en) Phosphoramidates for the treatment of hepatitis b virus
PH12021553231A1 (en) Hepatitis b core protein allosteric modulators
MX2022011756A (es) Tratamiento combinado con un agonista de tlr7 y un inhibidor del ensamblaje de la capsida del vhb.
JOP20170130A1 (ar) مركبات لمعالجة عدوى فيروس التهاب الكبد الوبائي b
HK1248278A1 (zh) 用於使乙型肝炎病毒基因表达沉默的组合物及方法
JOP20180008A1 (ar) مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b
AR111908A1 (es) Composiciones terapéuticas y métodos de tratamiento de hepatitis b
PH12014500369A1 (en) Influenza h5 vaccines
GB201114633D0 (en) Anti-viral therapy
EP3515929A4 (fr) Vaccins thérapeutiques contre le virus de l'hépatite b
JOP20190214A1 (ar) ثنائي هيدرو إيندين-?-كربوكساميدات ونظائر منها بها استبدال، وطرق تستخدمها
PH12017500820A1 (en) Combination long acting compositions and methods for hepatitis c
PH12017500816A1 (en) Long acting pharmaceutical compositions for hepatitis c
MX360137B (es) Proteínas h5 del virus de la influenza h5n1 para usarse como un medicamento.
IL271491B1 (en) Treatment of carcinoma of the liver characterized by hepatitis b virus infection
TH170861A (th) โอลิโกเมอร์และสิ่งควบคู่โอลิโกเมอร์
JO3769B1 (ar) علاج RNAi لعدوى فيروس التهاب الكبد B